Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ERIC CLL 2026 | Positioning BTK degraders in the CLL treatment sequence

Stephan Stilgenbauer, MD, University of Ulm, Ulm, Germany, discusses the potential role of BTK degraders in the treatment sequence for patients with chronic lymphocytic leukemia (CLL), noting that these novel agents typically enter the treatment landscape in later lines of therapy. Prof. Stilgenbauer suggests that tacabrutideg, a BTK degrader, is a prime candidate for combination with other agents and potential use in earlier lines of treatment due to its tolerability profile and efficacy. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.